Select the drug indication to add to your list


Viral infections
Only 4 drugs may be compared at once

Generic Name and Formulations:

Ganciclovir sodium 500mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution.

Select therapeutic use:

Indications for CYTOVENE IV:

Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including those with AIDS. Prevention of CMV disease in high-risk transplant recipients.


Give by IV infusion over 1 hour. Induction for CMV retinitis: 5mg/kg every 12 hours for 14–21 days. Maintenance: 5mg/kg once daily for 7 days per week or 6mg/kg once daily for 5 days per week. Prevention of CMV (transplant): 5mg/kg every 12 hours for 7–14 days, then 5mg/kg once daily for 7 days per week or 6mg/kg once daily for 5 days per week. Renal impairment, hemodialysis: adjust or reduce dose; see full labeling.


Not established.


Valganciclovir hypersensitivity.


Risk of hematologic toxicity; monitor CBCs and platelets frequently esp. in patients with renal dysfunction, history of leukopenia with ganciclovir or other nucleoside analogues, baseline neutrophil count <1000cells/microliter. ANC <500cells/microliter, hemoglobin <8g/dL, platelets <25,000cells/microliter: not recommended. Pre-existing cytopenias or history of cytopenic reactions to other drugs, chemicals, or irradiation. Potential to cause impairment of fertility, fetal toxicity (obtain pregnancy test before initiation), cancer. Renal impairment. Monitor ophthalmic and renal function. Maintain adequate hydration. Avoid contact with skin, mucous membranes. Use effective contraception during and for at least 30 days (females) or 90 days (males) after treatment. Pregnancy, nursing mothers: not recommended.


Avoid imipenem-cilastatin (seizures). Monitor renal function with concomitant cyclosporine, amphotericin B. Caution with myelosuppressive or other nephrotoxic drugs (eg, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/sulfamethoxazole, vinblastine, vincristine, zidovudine). Monitor for toxicity with didanosine. May be potentiated by probenecid.

Pharmacological Class:

Nucleoside analogue.

Adverse Reactions:

Pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, blood creatinine increased, thrombocytopenia; retinal detachment.

How Supplied:

Vials (10mL)—5